Opus Genetics to Present at the Chardan Annual Healthcare Conference
Opus Genetics (Nasdaq: IRD) announced that management will present at the Chardan Annual Healthcare Conference on October 20, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Opus Genetics (Nasdaq: IRD) announced that management will present at the Chardan Annual Healthcare Conference on October 20, 2026.
The presentation is scheduled for 10:00 a.m. ET. A link to the live and archived webcast will be available on the company’s website under Investors: Events.
Details
Market Reaction – IRD
On Oct 13, the day this news came out, the latest delayed price for IRD is 5.17% below the previous close. Our momentum scanner has recorded 12 alerts for this stock so far that day. The latest delayed price is $4.40.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
AI-generated analysis. How Rhea-AI works. Not financial advice.
RESEARCH TRIANGLE PARK, N.C., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), announced today that management will present at the Chardan Annual Healthcare Conference on Tuesday, October 20, 2026 at 10:00 a.m. ET.
A link to the live and archived webcast may be accessed on Opus Genetics’ website under the Investors section: Events.
About Opus Genetics
Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs). The Company is developing durable, one-time treatments designed to address the underlying genetic causes of severe retinal disorders. The Company’s pipeline includes seven AAV-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RDH12, MERTK, RHO, CNGB1 and NMNAT1. The Company is based in Research Triangle Park, NC. For more information, visit www.opusgtx.com.
Contacts:
Investors
Jenny Kobin
Remy Bernarda
IR Advisory Solutions
ir@opusgtx.com
Media
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com
Source: Opus Genetics, Inc.
